Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus

BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such as elderly and/or cirrhotic patients, and to elucidate the factors contrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamai, Hideyuki, Ida, Yoshiyuki, Kawashima, Akira, Shingaki, Naoki, Shimizu, Ryo, Moribata, Kosaku, Nasu, Tetsushi, Maekita, Takao, Iguchi, Mikitaka, Kato, Jun, Nakao, Taisei, Kitano, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491091/
https://www.ncbi.nlm.nih.gov/pubmed/28506030
http://dx.doi.org/10.5009/gnl16525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491091/
https://www.ncbi.nlm.nih.gov/pubmed/28506030
http://dx.doi.org/10.5009/gnl16525

Ejemplares similares